Previous close | 33.56 |
Open | 33.56 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 33.27 - 33.89 |
52-week range | 22.70 - 33.89 |
Volume | |
Avg. volume | 1,225,384 |
Market cap | 14.441B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 209.94 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.45 (1.34%) |
Ex-dividend date | 03 May 2024 |
1y target est | N/A |
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicineFDA granted provisional determination for interchangeability designation for Pyzchiva®Extends Sandoz immunology portfolio and further strengthens biosimilar position Expected to be among first wave of ustekinumab biosimilars to launch in US Basel,
Michel Robidoux Michel Robidoux PrSandoz® Lisdexamfetamine, one of first generic equivalents of Vyvanse*, available on Canadian marketApproved for all indications of reference medicine: Attention Deficit Hyperactivity Disorder and Binge Eating Disorder in adultsPrSandoz® Amoxicillin, PrSandoz® Desvenlafaxine and PrSandoz® Riociguat also joined Sandoz Canada’s generics portfolio this spring BOUCHERVILLE, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada announced today the launch of PrSando
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in gener